收费全文 | 2812篇 |
免费 | 370篇 |
国内免费 | 42篇 |
耳鼻咽喉 | 11篇 |
儿科学 | 44篇 |
妇产科学 | 13篇 |
基础医学 | 527篇 |
口腔科学 | 51篇 |
临床医学 | 305篇 |
内科学 | 340篇 |
皮肤病学 | 80篇 |
神经病学 | 348篇 |
特种医学 | 208篇 |
外科学 | 174篇 |
综合类 | 224篇 |
一般理论 | 1篇 |
预防医学 | 436篇 |
眼科学 | 38篇 |
药学 | 215篇 |
3篇 | |
中国医学 | 101篇 |
肿瘤学 | 105篇 |
2023年 | 24篇 |
2022年 | 76篇 |
2021年 | 111篇 |
2020年 | 110篇 |
2019年 | 147篇 |
2018年 | 139篇 |
2017年 | 149篇 |
2016年 | 164篇 |
2015年 | 129篇 |
2014年 | 190篇 |
2013年 | 235篇 |
2012年 | 149篇 |
2011年 | 178篇 |
2010年 | 141篇 |
2009年 | 131篇 |
2008年 | 129篇 |
2007年 | 123篇 |
2006年 | 112篇 |
2005年 | 105篇 |
2004年 | 74篇 |
2003年 | 82篇 |
2002年 | 70篇 |
2001年 | 67篇 |
2000年 | 50篇 |
1999年 | 46篇 |
1998年 | 22篇 |
1997年 | 17篇 |
1996年 | 11篇 |
1995年 | 19篇 |
1994年 | 14篇 |
1993年 | 10篇 |
1992年 | 19篇 |
1991年 | 16篇 |
1990年 | 13篇 |
1989年 | 13篇 |
1988年 | 9篇 |
1987年 | 12篇 |
1986年 | 11篇 |
1985年 | 11篇 |
1984年 | 14篇 |
1983年 | 8篇 |
1982年 | 9篇 |
1981年 | 10篇 |
1980年 | 6篇 |
1979年 | 8篇 |
1978年 | 6篇 |
1977年 | 4篇 |
1976年 | 7篇 |
1975年 | 8篇 |
1973年 | 5篇 |
Areas covered: Here, the impact of hereditary genes considered in drug labels such as thiopurine S-methyltransferase (TPMT), UDP-glucuronosyltransferase 1A1 (UTG1A1) and dihydropyrimidine dehydrogenase (DPYD) are discussed with respect to guidelines of the Clinical Pharmacogenetics Implementation Consortium (CPIC). Moreover, the association between genetic variants of drug transporters with the clinical outcome is comprehensively discussed.
Expert opinion: Precision therapy in the field of oncology is developing tremendously. There are a number of somatic tumor genetic markers that are indicative for treatment with anti-cancer drugs. By contrast, for some hereditary variants, recommendations have been developed. Although we have vast knowledge on the association between drug transporter variants and clinical outcome, the overall data is inconsistent and the predictability of the related phenotype is low. Further developments in research may lead to the discovery of rare, but functionally relevant single nucleotide polymorphisms and a better understanding of multiple genomic, epigenomic as well as phenotypic factors, contributing to drug response in malignancies. 相似文献
Areas covered: Incorporation of vitamin-E in nanocarriers have the advantage of (1) improving the hydrophobicity of the drug delivery system, thereby improving the solubility of the loaded poorly soluble anticancer drugs, (2) enhancing the biocompatibility of the polymeric drug carriers, and (3) improving the anticancer potential of the chemotherapeutic agents by reversing the cellular drug resistance via simultaneous administration. In addition to being a powerful antioxidant, vitamin E demonstrated its anticancer potential by inducing apoptosis in various cancer cell lines. Various vitamin E analogs have proven their ability to cause marked inhibition of drug efflux transporters.
Expert opinion: The review discusses the potential of incorporating vitamin E in the polymeric micelles which are designed to carry poorly water-soluble anticancer drugs. Current applications of various vitamin E-based polymeric micelles with emphasis on the use of α-tocopherol, D-α-tocopheryl succinate (α-TOS) and its conjugates such as D-α-tocopheryl polyethylene glycol-succinate (TPGS) in micellar system is delineated. Advantages of utilizing polymeric micelles for drug delivery and the challenges to treat cancer, including multiple drug resistance have been discussed. 相似文献